Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q5JPH6
UPID:
SYEM_HUMAN
Alternative names:
Glutamyl-tRNA synthetase
Alternative UPACC:
Q5JPH6; B3KTT2; D3DWF1; Q86YH3; Q8TF31
Background:
The Probable glutamate--tRNA ligase, mitochondrial, also known as Glutamyl-tRNA synthetase, plays a critical role in protein synthesis. It catalyzes the attachment of glutamate to tRNA(Glu) in a two-step reaction, crucial for mitochondrial function and cellular energy production.
Therapeutic significance:
Linked to Combined oxidative phosphorylation deficiency 12, a severe neurologic disorder, understanding the role of Probable glutamate--tRNA ligase could open doors to potential therapeutic strategies, offering hope for treatments targeting mitochondrial dysfunctions.